Syndax Pharmaceuticals(NASDAQ) SNDX

Syndax makes medicines to treat specific types of cancer. These products help people with rare and aggressive blood diseases. The company targets the biological triggers that cause tumors to grow.

New Treatments for Blood Cancers

• Revuforj: Oral tablet that blocks the menin protein, which helps cancer cells grow; approved for patients with KMT2A gene translocations or NPM1 mutations.
• Niktimvo: Injectable antibody that treats chronic graft-versus-host disease (cGVHD); blocks a specific receptor to stop donor cells from attacking a patient's body after a transplant.
• Entinostat: Small molecule drug designed to improve how the immune system reacts to cancer; currently licensed for use in China.

Strategic Deals and Partnerships

• Formed a partnership with Incyte in September 2021 to develop and sell Niktimvo worldwide.
• Signed a $350 million deal with Royalty Pharma in November 2024 to sell future royalty rights for Niktimvo in the United States.
• Licensed the core technology for Revuforj from Vitae Pharmaceuticals, a subsidiary of AbbVie, in October 2017.
• Expanded into the Chinese market through a licensing agreement with Eddingpharm for the drug entinostat.
• Secured global rights to Niktimvo through a 2016 agreement with UCB.

Clinical and Operational Strengths

Syndax holds a first-mover advantage with the first approved treatments for two specific genetic leukemia subtypes. The company uses a collaborative model, sharing development costs and commercial rights with large pharmaceutical partners to expand its market reach.

Measuring Recent Fiscal Progress

• Revenue was $68.5 million in Q4 2025, up 791.7% from $7.7 million in Q4 2024.
• Operating income reached a loss of $62.5 million in Q4 2025, which narrowed (improved) by 35.1% from the previous year.
• Net income was a loss of $68.0 million in Q4 2025, an improvement of 27.8% compared to the loss in Q4 2024.
• Free cash flow was negative $69.5 million in Q4 2025, worsening by 21.2% from the same period in 2024.

Bottom Line

Syndax has transitioned from a research-focused firm to a commercial-stage company with two approved therapies. Its strategy relies on targeted genetic treatments and high-value partnerships to drive growth in the cancer treatment market.